Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS.

Ohagen A, Devitt A, Kunstman KJ, Gorry PR, Rose PP, Korber B, Taylor J, Levy R, Murphy RL, Wolinsky SM, Gabuzda D.

J Virol. 2003 Nov;77(22):12336-45.

2.

Medicine. The need for a global HIV vaccine enterprise.

Klausner RD, Fauci AS, Corey L, Nabel GJ, Gayle H, Berkley S, Haynes BF, Baltimore D, Collins C, Douglas RG, Esparza J, Francis DP, Ganguly NK, Gerberding JL, Johnston MI, Kazatchkine MD, McMichael AJ, Makgoba MW, Pantaleo G, Piot P, Shao Y, Tramont E, Varmus H, Wasserheit JN.

Science. 2003 Jun 27;300(5628):2036-9.

PMID:
12829768
3.

Antibody neutralization of human immunodeficiency virus type 1 (HIV-1).

Sch√łnning K.

APMIS Suppl. 2003;(111):1-42. Review. No abstract available.

PMID:
12739253
5.

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.

Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinger H, Parren PW, Robinson J, Van Ryk D, Wang L, Burton DR, Freire E, Wyatt R, Sodroski J, Hendrickson WA, Arthos J.

Nature. 2002 Dec 12;420(6916):678-82.

PMID:
12478295
6.

Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques.

Fouts T, Godfrey K, Bobb K, Montefiori D, Hanson CV, Kalyanaraman VS, DeVico A, Pal R.

Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11842-7. Epub 2002 Aug 21.

7.

Diversity considerations in HIV-1 vaccine selection.

Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B.

Science. 2002 Jun 28;296(5577):2354-60. Review.

PMID:
12089434
8.

Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells.

Mascola JR, Louder MK, Winter C, Prabhakara R, De Rosa SC, Douek DC, Hill BJ, Gabuzda D, Roederer M.

J Virol. 2002 May;76(10):4810-21.

9.

Association of chemokine-mediated block to HIV entry with coreceptor internalization.

Brandt SM, Mariani R, Holland AU, Hope TJ, Landau NR.

J Biol Chem. 2002 May 10;277(19):17291-9. Epub 2002 Jan 8.

10.

Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion.

Finnegan CM, Berg W, Lewis GK, DeVico AL.

J Virol. 2001 Nov;75(22):11096-105.

11.

Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.

Letvin NL, Robinson S, Rohne D, Axthelm MK, Fanton JW, Bilska M, Palker TJ, Liao HX, Haynes BF, Montefiori DC.

J Virol. 2001 May;75(9):4165-75.

12.

Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.

Cho MW, Kim YB, Lee MK, Gupta KC, Ross W, Plishka R, Buckler-White A, Igarashi T, Theodore T, Byrum R, Kemp C, Montefiori DC, Martin MA.

J Virol. 2001 Mar;75(5):2224-34.

13.

Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex.

Fouts TR, Tuskan R, Godfrey K, Reitz M, Hone D, Lewis GK, DeVico AL.

J Virol. 2000 Dec;74(24):11427-36.

14.

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.

Berger EA, Murphy PM, Farber JM.

Annu Rev Immunol. 1999;17:657-700. Review.

PMID:
10358771
15.

Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.

Rossio JL, Esser MT, Suryanarayana K, Schneider DK, Bess JW Jr, Vasquez GM, Wiltrout TA, Chertova E, Grimes MK, Sattentau Q, Arthur LO, Henderson LE, Lifson JD.

J Virol. 1998 Oct;72(10):7992-8001.

16.

Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity.

LaCasse RA, Follis KE, Moudgil T, Trahey M, Binley JM, Planelles V, Zolla-Pazner S, Nunberg JH.

J Virol. 1998 Mar;72(3):2491-5.

17.

Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage.

Montefiori DC, Collman RG, Fouts TR, Zhou JY, Bilska M, Hoxie JA, Moore JP, Bolognesi DP.

J Virol. 1998 Mar;72(3):1886-93.

18.

Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.

Trkola A, Ketas T, Kewalramani VN, Endorf F, Binley JM, Katinger H, Robinson J, Littman DR, Moore JP.

J Virol. 1998 Mar;72(3):1876-85.

19.

Compact, synthetic, vaccinia virus early/late promoter for protein expression.

Chakrabarti S, Sisler JR, Moss B.

Biotechniques. 1997 Dec;23(6):1094-7.

PMID:
9421642
20.

Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.

VanCott TC, Mascola JR, Kaminski RW, Kalyanaraman V, Hallberg PL, Burnett PR, Ulrich JT, Rechtman DJ, Birx DL.

J Virol. 1997 Jun;71(6):4319-30.

Supplemental Content

Support Center